Ultomiris is administered intravenously by a healthcare professional, with infusion times varying from 24 to 90 minutes or more depending on the dose. The dosage of Ultomiris is determined by body ...
Alexion Pharmaceuticals, Inc. ALXN announced that the FDA has accepted its supplemental biologics license application (sBLA) for its long-acting C5 complement inhibitor, Ultomiris (ravulizumab-cwvz), ...
Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.
Alexion Pharmaceuticals, Inc. ALXN announced that the FDA approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of children (aged one month and above) as well as adolescents ...
When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper ...
AstraZeneca is making new progress with its Ultomiris expansion plan. On the heels of an FDA approval, the C5 inhibitor has returned with a clinical win in a rare autoimmune disease affecting the ...
Credit: Shutterstock. The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor. The ...
Results from CHAMPION-NMOSD trial demonstrated ULTOMIRIS reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo ULTOMIRIS also showed a lower proportion of patients experiencing ...
The safety and efficacy of Ultomiris in patients with PNH was assessed in 2 open-label, randomized, active-controlled, non-inferiority Phase 3 studies. The Food and Drug Administration (FDA) has ...
AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results